Is Schrodinger (SDGR) overvalued or fairly valued?

MarketChacha shows Schrodinger's valuation in context — a forward P/E of about -9.0, a price-to-book of about 3.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Schrodinger's revenue?

Schrodinger reported revenue of $255.9M for FY2025, with net profit of $-103.3M, per official filings.

What is the share price of Schrodinger (SDGR)?

Schrodinger last traded at $14.96 (-1.0% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Schrodinger

SDGR · NYSE · Healthcare · United States

$14.96-1.0%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:32 PM

Snapshot

TickerSDGR

ExchangeNYSE

SectorHealthcare

IndustryHealth Information Services

CountryUnited States

Employees850

HeadquartersNew York, United States

Market cap$1.1B

P/B3.6

Volume394.26K

Websitewww.schrodinger.com

Filings tracked6

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Profile as reported by Yahoo Finance.

Who owns it

Insiders3.0%
Institutions97.0%
Public & other0.0%

323 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.14.76%
Gates Foundation Trust10.65%
Rubric Capital Management LP9.15%
Vanguard Portfolio Management LLC5.89%
Sumitomo Mitsui Trust Group, Inc.4.87%
Amova Asset Management Americas Inc4.87%
Massachusetts Financial Services Co.4.10%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC4.06%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 59.2 points over the period — profitability is trending down.

Net margin trend18.8% → -40.4%

Margin has compressed by about 59.2 points over the period — profitability is trending down.

Return on equity-28.4%

Latest ROE of -28.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $53.7M · EPS -0.64

Est. earnings growth -12.3%

Next fiscal year

Rev $265.1M · EPS -1.66

Est. earnings growth +26.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$10.9552-wk range$23.75

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.1B

Day change

-1.0%

Fwd P/E

-9.0

P/B

3.6

Beta

1.62

Revenue (FY2025)

$255.9M

Net margin

-40.4%

ROE

-28.4%

Revenue CAGR (2y)

+8.7%

EPS (FY2025)

-1.41

Net profit (FY2025)

$-103.3M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about SDGR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$255.9M	$-103.3M	-1.41	-40.4%	-28.4%
FY2024	$207.5M	$-187.1M	-2.57	-90.2%	-44.4%
FY2023	$216.7M	$40.7M	0.54	18.8%	7.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$58.6M	$-60.0M	-0.81	-102.5%
2025Q3	$54.3M	$-32.8M	-0.45	-60.4%
2025Q2	$54.8M	$-43.2M	-0.59	-78.8%
2025Q1	$59.6M	$-59.8M	-0.82	-100.4%
2024Q3	$35.3M	$-38.1M	-0.52	-108.1%
2024Q2	$47.3M	$-54.0M	-0.74	-114.2%
2024Q1	$36.6M	$-54.7M	-0.76	-149.5%
2023Q3	$42.6M	$-62.0M	-0.86	-145.7%
2023Q2	$35.2M	$4.3M	0.06	12.2%
2023Q1	$64.8M	$129.1M*	1.75	—

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure
SEC6/29/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/23/2026material
8-K — Executive/director change, Exhibits
SEC6/8/2026material
8-K — Executive/director change, Reg FD disclosure
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.